Edition:
United Kingdom

Yield10 Bioscience Inc (YTEN.OQ)

YTEN.OQ on NASDAQ Stock Exchange Capital Market

1.42USD
15 Oct 2018
Change (% chg)

$0.03 (+2.16%)
Prev Close
$1.39
Open
$1.44
Day's High
$1.44
Day's Low
$1.37
Volume
10,858
Avg. Vol
15,663
52-wk High
$8.67
52-wk Low
$1.13

Latest Key Developments (Source: Significant Developments)

Yield10 Bioscience Signs Research License Agreement
Wednesday, 8 Aug 2018 

Aug 8 (Reuters) - Yield10 Bioscience Inc ::YIELD10 BIOSCIENCE SIGNS RESEARCH LICENSE AGREEMENT COVERING CRISPR-CAS9 GENOME-EDITING TECHNOLOGY WITH THE BROAD INSTITUTE AND PIONEER.YIELD10 BIOSCIENCE - JOINT LICENSE COVERS IP CONSISTING OF CRISPR-CAS9 TECHNOLOGY PATENTS & PATENT APPLICATIONS CONTROLLED BY BROAD INSTITUTE AND PIONEER.  Full Article

Yield10 Bioscience Announces Pricing Of $12.6 Mln Public Offering
Tuesday, 19 Dec 2017 

Dec 19 (Reuters) - Yield10 Bioscience Inc ::YIELD10 BIOSCIENCE ANNOUNCES PRICING OF $12.6 MILLION PUBLIC OFFERING.YIELD10 BIOSCIENCE INC - OFFERING HAS 3.8 MILLION CLASS A UNITS, PRICED AT $2.25 PER UNIT, AND 3,987 CLASS B UNITS, PRICED AT $1,000 PER UNIT.  Full Article

Yield10 Bioscience Grants Research License To Monsanto To Evaluate Two Novel Yield Traits In Soybean
Monday, 11 Dec 2017 

Dec 11 (Reuters) - Monsanto Co ::YIELD10 BIOSCIENCE INC - ‍GRANTED A NON-EXCLUSIVE RESEARCH LICENSE TO MONSANTO COMPANY TO EVALUATE ITS NOVEL C3003 AND C3004 YIELD TRAITS IN SOYBEAN​.YIELD10 BIOSCIENCE INC - ‍UNDER LICENSE, MONSANTO PLANS TO RESEARCH BOTH TRAITS WITHIN ITS SOYBEAN PIPELINE AS A STRATEGY TO IMPROVE PLANT YIELDS​.  Full Article

Yield10 Bioscience posts Q3 loss $0.59/shr from continuing operations
Thursday, 9 Nov 2017 

Nov 9 (Reuters) - Yield10 Bioscience Inc :Yield10 Bioscience announces third quarter 2017 financial results.Q3 loss per share $0.59 from continuing operations.Q3 revenue $200,000 versus $500,000.Yield10 Bioscience Inc - expects to use about $8.0 million to $8.5 million in cash for FY 2017, including anticipated payments for restructuring costs​.Yield10 Bioscience Inc - expects current cash resources will be sufficient to fund operations & meet obligations into Q1 2018​.Yield10 - "the ‍company's present capital resources raise substantial doubt, however, about company's ability to continue as a going concern"​.  Full Article